Post-acute COVID-19 functional movement disorder

Garg, Alpana; Goyal, Shubham; Comellas, Alejandro P.

doi:10.1177/2050313x211039377

Cited by 12 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These cognitive symptoms were associated with the presence of hypometabolic clusters in the brains of patients with PACS, as demonstrated using fluorodeoxyglucose (FDG)-positron emission tomography (PET) 30 . In addition, a recent case report described a patient that presented with a movement disorder after COVID-19 infection 14 . Previous studies showed a surge in tics and tic-like attacks during the COVID-19 pandemic, suggesting that this surge was due to the stress induced by the pandemic 16 .…”

Section: Discussionmentioning

confidence: 99%

“…The studies performed regarding PACS indicated that COVID-19 survivors might suffer from long-term debilitating symptoms after their recovery 12 . Although several studies have characterized these symptoms, most of them were performed on hospitalized COVID-19 patients, and new symptoms are still being reported, such as movement disorders 14 . In addition, the duration of time that should elapse for these symptoms to subside has not yet been studied.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

New symptoms and prevalence of postacute COVID-19 syndrome among nonhospitalized COVID-19 survivors

Albtoosh

Toubasi

Oweidat

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to assess postacute coronavirus disease 2019 (COVID-19) syndrome (PACS) symptoms according to the onset of the infection while evaluating the effect of COVID-19 vaccination on the symptoms of PACS. We conducted a retrospective single-center cohort study in which nonhospitalized COVID-19 survivors and healthy controls were compared for the occurrence of PACS. The total number of patients in this study was 472. At 6–12 and > 12 months after the infection, COVID-19 survivors had a significantly higher incidence of posttraumatic stress disorder (PTSD) and anxiety than the non-COVID-19 cohort. Furthermore, depression, cognitive deficit, tics, impaired quality of life and general health impairment were significantly more prevalent among COVID-19 survivors at < 6 months, 6–12 months and > 12 months than in the non-COVID-19 cohort. However, respiratory symptoms were significantly more prevalent among COVID-19 survivors only in the first 6 months after infection. In addition, cognitive deficit (OR = 0.15; 95% CI 0.03–0.87) and impaired quality of life (B = − 2.11; 95% CI − 4.21 to − 0.20) were significantly less prevalent among vaccinated COVID-19 survivors than among nonvaccinated survivors. Longitudinal studies are needed to establish the time that should elapse after COVID-19 infection for the symptoms of PACS to appear. Randomized clinical trials are needed to assess the possibility that COVID-19 vaccines might relieve PACS symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

New symptoms and prevalence of postacute COVID-19 syndrome among nonhospitalized COVID-19 survivors

Albtoosh

Toubasi

Oweidat

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…This study further unveiled alterations of multiple common factors involved in cognitive impairment observed in COVID-19 and AD. There is evidence that SARS-CoV-2 can aggravate the clinical presentations of PD [ 173 , 174 , 175 , 176 ] and cause de novo problems with gait, movement, coordination, and balance [ 177 , 178 , 179 , 180 ]. The lasting impacts of SARS-CoV-2 infection on microglial plasticity and its contribution to the pathophysiology of post-COVID-19 neurological sequelae and disorders, including PD, were comprehensively discussed in a recent review [ 181 ].…”

Section: Covid-19 and Neurodegenerationmentioning

confidence: 99%

A Peek into Pandora’s Box: COVID-19 and Neurodegeneration

Chandra¹,

Johri²

2022

Brain Sciences

View full text Add to dashboard Cite

Ever since it was first reported in Wuhan, China, the coronavirus-induced disease of 2019 (COVID-19) has become an enigma of sorts with ever expanding reports of direct and indirect effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on almost all the vital organ systems. Along with inciting acute pulmonary complications, the virus attacks the cardiac, renal, hepatic, and gastrointestinal systems as well as the central nervous system (CNS). The person-to-person variability in susceptibility of individuals to disease severity still remains a puzzle, although the comorbidities and the age/gender of a person are believed to play a key role. SARS-CoV-2 needs angiotensin-converting enzyme 2 (ACE2) receptor for its infectivity, and the association between SARS-CoV-2 and ACE2 leads to a decline in ACE2 activity and its neuroprotective effects. Acute respiratory distress may also induce hypoxia, leading to increased oxidative stress and neurodegeneration. Infection of the neurons along with peripheral leukocytes’ activation results in proinflammatory cytokine release, rendering the brain more susceptible to neurodegenerative changes. Due to the advancement in molecular biology techniques and vaccine development programs, the world now has hope to relatively quickly study and combat the deadly virus. On the other side, however, the virus seems to be still evolving with new variants being discovered periodically. In keeping up with the pace of this virus, there has been an avalanche of studies. This review provides an update on the recent progress in adjudicating the CNS-related mechanisms of SARS-CoV-2 infection and its potential to incite or accelerate neurodegeneration in surviving patients. Current as well as emerging therapeutic opportunities and biomarker development are highlighted.

show abstract

“…Frequently, fatigue and anxiety are also part of the disease spectrum [ 17 ]. Various authors reported an increase in the incidence of FMD during the COVID-19 pandemic, possibly in relation to a higher level of stress [ 18 , 19 ]. Hull et al reported an increase of 60% in the number of patients diagnosed with FMD during the pandemic [ 18 ].…”

Section: Neurological Impairment In Covid-19mentioning

confidence: 99%

Neurological Manifestations of SARS-CoV2 Infection: A Narrative Review

et al. 2022

View full text Add to dashboard Cite

The COVID-19 virus frequently causes neurological complications. These have been described in various forms in adults and children. Headache, seizures, coma, and encephalitis are some of the manifestations of SARS-CoV-2-induced neurological impairment. Recent publications have revealed important aspects of viral pathophysiology and its involvement in nervous-system impairment in humans. We evaluated the latest literature describing the relationship between COVID-19 infection and the central nervous system. We searched three databases for observational and interventional studies in adults published between December 2019 and September 2022. We discussed in narrative form the neurological impairment associated with COVID-19, including clinical signs and symptoms, imaging abnormalities, and the pathophysiology of SARS-CoV2-induced neurological damage.

show abstract

Post-acute COVID-19 functional movement disorder

Cited by 12 publications

References 17 publications

New symptoms and prevalence of postacute COVID-19 syndrome among nonhospitalized COVID-19 survivors

New symptoms and prevalence of postacute COVID-19 syndrome among nonhospitalized COVID-19 survivors

A Peek into Pandora’s Box: COVID-19 and Neurodegeneration

Neurological Manifestations of SARS-CoV2 Infection: A Narrative Review

Contact Info

Product

Resources

About